Fig. 4: Survival curves according to the copy number of ACTN4 (US cohort).

Kaplan–Meier estimate of DFS (a) and BCSS (b) of patients with HR-positive, HER2-negative, node-negative invasive breast cancer carrying (red) and not carrying (black) ACTN4 CNI. Differences between the curves were assessed using the log-rank test.